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Objectives: To investigate the role of HER-2/neu-mediated COX-2/P450arom signal in estrogen-dependent
endometrial carcinoma.
Methods: The recombinant eukaryotic expression vector, pcDNA3.1-HER-2/neu, was constructed and transfect to
Ishikawa endometrial carcinoma cells. The expression of COX-2 and P450arom in transfected cells were detected by
real-time PCR and western blotting. The levels of estrogen in cell supernatants were detected by ELISA.
Results: Over-expression of HER-2/neu in transfected cells was confirmed by real-time PCR and western blotting.
The levels of autocrine estrogen in transfected cells was significantly increased which combination with the
enhancement of COX-2 and P450arom expression in transfected cells.
Conclusion: HER-2/neu induced the improvement of autocrine estrogen in endometrial carcinoma cell through
triggering the COX-2/P450arom signal.
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Endometrial carcinoma is a common gynecologic malig-
nancy with uncharacterized molecular mechanisms of
pathogenesis. A large body of studies has reported that
the origin of endometrial carcinoma was associated with
long-term estrogen stimulation without counteraction
[1]. Long-term stimulation of estrogen can cause endo-
metrial hyperplasia, even atypical hyperplasia, and can
progress to carcinogenesis. Local synthesis of estrogen
may also lead to endometrial carcinoma. A better under-
standing of the mechanisms of local estrogen synthesis
is important to find the new treatment of endometrial
carcinoma.
Aromatase (P450arom), a key enzyme for the bio-
synthesis of estrogens, was detectably active and over-
expressed in endometrial carcinoma, whereas it was
undetectable in normal endometria. P450arom is the* Correspondence: maxiaoxin666@yahoo.com.cn
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reproduction in any medium, provided the orrate-limiting enzyme that catalyzes the final step in the
conversion pathway from androgen to estrogen. The
quantity and activity of P450arom can directly affect
the levels of estrogen in normal or abnormal tissues, in
order to maintain estrogen-related physiologic func-
tions in normal tissues. Meanwhile, P450arom play a
role in the pathogenesis and prognosis of estrogen-
dependent diseases. The activity of P450arom is regu-
lated by prostaglandin E2 (PGE2), which is affected by
cyclooxygenase-2 (COX-2). We hypothesize that COX-
2/PGE2/P450arom might be a signaling pathway in
estrogen-dependent diseases to regulate the autocrine
activity of estrogen in cancerous tissues. Previous
reports indicated that HER-2/neu regulated the expres-
sion of COX-2 as the upstream molecular of COX-2-
mediated signal pathways [2,3]. In the present paper, our
results demonstrated that transfection with HER-2/neu in
endometrial cells induced the activation of COX-2/PGE2/
P450arom signal, resulting in the increase of autocrine
estrogen from endometrial cells.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Cell culture
The Ishikawa cell line was kindly supplied by the Depart-
ment of Pathophysiology, Beijing University. Cells were cul-
tured in RIPM1640 with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin in an incubator
maintained at 37°C and 5% CO2. Celecoxib, a selective
COX-2 inhibitor, was purchased from Santa Cruz Biotech-
nology and dissolved in DMSO to generate a 100 mM
stock solution that was stored at −20°C. For inhibition ex-
periment, confluence cells were starved by serum
deprivation overnight. Then, cells were treated with 80 μM




primers were designed based on HER-2/neu cDNA se-
quence obtained from GenBank. For cloning, HindIII/
XbaI restriction endonuclease sites were inserted flanking
the target gene primers. Primers were synthesized by
TaKaRa Biotechnology Co., Ltd. Total RNA was isolated
from Ishikawa cells using TRIzol reagent (TaKaRa, China)
according to the manufacturer’s instructions. HER-2/neu
cDNA was reverse-transcribed using the One Step RNA
PCR Kit (TaKaRa) according to the manufacturer’s recom-
mendations. PCR conditions included denaturation at
94°C for 5 min, 25 cycles of denaturation at 94°C for 45 s,
annealing at 60°C for 1 min, and extension at 72°C for
6 min, with a final extension at 72°C for 10 min. PCR
products were separated on 1% agarose gel and eluted.
The PCR product was sent to TaKaRa for sequencing.Figure 1 RT-PCR and digestion products. A. HER-2/neu RT-PCR, Marker:PcDNA3.1 plasmid and HER2 cDNA were digested with
HindIII/XbaI double endonucleases. The digested pro-
ducts were separated by agarose gel electrophoresis and
purified. Pure HER2 cDNA and vector were mixed at a 4:1
ratio and were ligated at 16°C for 20 h. Ligation products
were transformed into E. coli. After culturing at 37°C over-
night, E. coli cells were screened. DNA was isolated from
positive colonies (named pcDNA3.1 (+)-HER2), and were
sequence-verified.
Gene transfection and G418 screening
pcDNA3.1 (+)-HER2 was isolated using a plasmid extrac-
tion kit (Invitrogen, USA) according to the manufacturer’s
protocol. Ishikawa cells in logarithmic growth were trans-
ferred to 6-well culture plates at 1 × 106 cells/well and
were cultured for 1 d prior to transfection. Ishikawa cells
then were transfected with pcDNA3.1-HER-2/neu or
pcDNA3.1 (control) using Lipofectamine2000 (Invitrogen,
USA) according to the manufacturer’s protocol. Non-
transfected cells were cultured as the negative control.
The original culture media was discarded 3 d after trans-
fection, and cells were cultured in complete media
containing 10% fetal bovine serum and 700 μg/ml of G418
(Invitrogen, USA). G418-resistant clones were selected
and transferred to culture media containing 350 μg/ml of
G418 for scale-up culture.
RNA interference
To knock down the HER2/neu in Ishikawa cells, the siRNA
transient transfection experiment was performed according
to the previous publication [4]. Briefly, Ishikawa cells
were transfected with 25 nM COX-2 siRNAs, respectively.λ-HindIII DNA marker; B. Digestion. Markker: λ-HindIII DNA marker.
Table 1 HER-2/neu mRNA expression
Group ΔCt -ΔΔCt 2-ΔΔCt
HER-2 transfected 97.16 ± 0.71 2.62 ± 0.71 6.15 (3.75–10.06)*
pcDNA3.1 transfected 9.88 ± 1.10 0.1 ± 0.10 1.07 (1.06–1.08)
Non-transfected 9.78 ± 1.09 0 ± 1.09 1 (0.47-2.13)
* P < 0.05.
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Transfections were carried out according to the guidelines
for the DharmaFECTW siRNA Transfection Reagents
(Dharmacon). Ishikawa cells were collected at 72 hours
post-siRNA addition for protein western blotting analysis.Real-time RT-PCR analysis of HER-2/neu
Total RNA was extracted from Ishikawa cells stably
transfected with pcDNA3.1 (+)-HER2 using TRIzol, as
above. The same HER-2/neu primers were used as in the
construction of pcDNA3.1 (+)-HER2. GAPDH was used as
the internal control (upstream 50-CATCCATGACAACT
TTGGTATC-30; downstream 50-CCATCACGCCACAGTT
TC-30). cDNA was synthesized from 1 μg of total RNA
using oligo(dT) primers in the presence of reverse tran-
scriptase. Gene amplification was performed on a real-time
PCR instrument (TaKaRa, China) using 1 μl of cDNA
as template in a 25 μl volume. PCR was started at 95°C for
5 min, followed by 30 cycles of denaturation at 95°C for
10 s, annealing at 59°C for 15 s, and extension at 72°C
for 20 s, with a final extension at 72°C for 10 min. Fluores-
cence intensity was monitored and recorded in real time. A
melting curve analysis was performed after amplification
was complete. The ΔΔCt value was used to evaluate ex-
pression levels of HER2 and COX-2 mRNA. By thisFigure 2 The levels of HER-2/neu, COX-2, and P450armo in over-expr
A. Represent image for western blot. B. Analysis of protein levels in each groumethod, a higher expression level is related to a lower
ΔΔCt value.
Western blotting for HER-2/neu, COX-2, and P450arom
Cells collected from non-transfected, pcDNA3.1-transfec-
ted, and pcDNA3.1-HER2-transfected groups were lysed
with 250 μl protein extracting fluid (RIPA lysis buffer:
50 mM Tris [pH 7.4], 150 mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS), homogenized for
10 min, incubated in an ice-bath for 1 h, and centrifuged
at 12,000 × g for 30 min at 4°C. Supernatants were col-
lected, and protein concentrations were determined using
the BCA protein assay system (Pierce, USA). Proteins
were separated by 12% SDS-PAGE and were transferred
to PVDF membranes. After blocking overnight at 4°C in
1 × PBS, 0.1% Tween 20, and 5% non-fat milk, membranes
were incubated with anti-HER-2/neu (1:800), COX-2
(1:400), P450arom (1:400) and β-actin (1:800) polyclonal
antibodies (Santa Cruz Biotechnology, USA) for 3 h at
room temperature. Membranes were washed twice and in-
cubated with horseradish peroxidase-conjugated goat anti-
rabbit secondary antibody (ZhongShan, China, 1:1,500) for
2 h at room temperature. Immunodetection was performed
by chemiluminescence (ECL reagent, Beyotime, China) and
membranes were exposed to film. Images were captured
using a transmission scanner. For quantification, target pro-
teins were normalized to β-actin (the internal standard) by
comparing the gray-scale values of proteins to correspond-
ing β-actin values. Quantification was performed using
UVP Gelworks ID Advanced v2.5 software (Bio-Rad, USA).
ELISA for PGE2 and E2 detection
Supernatants were collected from non-transfected,
pcDNA3.1-transfected, and pcDNA3.1-HER2-transfectedessed HER2 ishikawa cells were detected by western blotting.
p and quantification of band density was done using Image J. * P < 0.05.
Table 2 ELISA analyses for PGE2 and E2 in the
supernatants of endometrial carcinoma cells
Group PGE2(pg/ml) E2 (pg/ml)
Transfected 41.69 ± 0.87* 31.49 ± 2.14*
pcDNA3.1 transfected 31.35 ± 1.06 21.16 ± 2.37
Non-transfected 27.67 ± 1.20 20.56 ± 3.27
* P < 0.05.
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tions were measured using an ELISA kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. Each sample was examined in triple and
averaged for data analysis.
Statistical methods
SPSS v10.0 software was used for all statistical analyses.
Data were expressed as mean ± standard error of the mean
(SEM). One-factor analysis of variance was used for
pairwise comparison. Statistical significance was defined
as P < 0.05.
Results
Construction of pcDNA3.1-HER2
RT-PCR of HER-2/neu yielded a specific band of approxi-
mately 4.4 kb (Figure 1A). The DNA fragment sizes from
HER-2/neu cDNA and pcDNA3.1 plasmid digested with
HindIII and XbaI were as predicted from the sequence
(Figure 1B). DNA sequencing confirmed the absence of
point or frameshift mutations in HER-2/neu cDNA.Expression of HER-2/neu in Ishikawa cells stably
transfected with pcDNA3.1-HER2
Real-time RT-PCR demonstrated significantly higher HER-
2/neu mRNA expression in pcDNA3.1-HER2-transfected
cells compared with empty plasmid-transfected or non-Figure 3 The levels of COX-2, and P450armo in the ishikawa cells tran
Analysis of protein levels in each group and quantification of band densitytransfected cells (Table 1). Western blotting indicated a sig-
nificant increase in HER-2/neu protein levels of cells
transfected with pcDNA3.1-HER2 compared with empty
plasmid-transfected or non-transfected cells (Figure 2).
These results imply that the transfection was effective, and
that the cells were appropriate for subsequent analyses.
Transfected with pcDNA3.1-HER2 in Ishikawa cells
induced the increase of COX-2, PGE2 and P450arom
expression
Western blotting demonstrated that levels of COX-2 and
P450arom in Ishikawa cells stably transfected with
pcDNA3.1-HER2 were significantly higher compared to
those in empty plasmid-transfected or non-transfected
cells (Figure 2). In additionally, ELISA analysis showed
that the supernatant level of PEG2 in pcDNA3.1-HER2-
transfected group was significant higher than that of
the empty plasmid-transfected group, and the normal
cell group.
Transfected with pcDNA3.1-HER2 induced the increase of
autocrine E2 from Ishikawa cells
ELISA indicated was there were statistically significant dif-
ferences in the cell supernatants of E2 levels among the
pcDNA3.1-HER2-transfected group, the empty plasmid-
transfected group, and the normal cell group (Table 2).Inhibition of HER2 in Ishikawa cells induced the decrease
of COX-2 and P450arom expression
RNA interference technology was used for the down-
regulation of HER2 expression in Ishikawa cells. As
shown in Figure 3, HER2 siRNAs were effectively able to
knockdown the levels of HER2 in Ishikawa cells. Inter-
estingly, down-regulation of HER2 expression induced
significantly the reduction of COX-2 and P450arom
levels in Ishikawa cells (Figure 3).sfencted with HER2 siRNA. A. Represent image for western blot. B.
was done using Image J. * P < 0.05.
Table 3 ELISA analysis for PGE2 in the supernatants of
tranfected endometrial carcinoma cells treated with
Celecoxib
Group Celecoxib - (pg/ml) Celecoxib + (pg/ml)
pcDNA3.1-HER-2 41.09 ± 2.76 33.86 ± 3.11*
pcDNA3.1 33.94 ± 3.41 30.56 ± 3.08
* P < 0.05.
Figure 4 The levels of P450armo in the ishikawa cells treated with 80 μM celecoxib. A. Represent image for western blot. B. Analysis of
protein levels in each group and quantification of band density was done using Image J. * P < 0.05.
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cells led to the decrease of PGE2 and P450arom
expression
To further investigate the relationship between the COX-2/
PGE2/P450arom signal and HER2, celecoxib, a selective
COX-2 inhibitor, was used for inhibition experiment. The
results showed that inhibition of COX-2 in the over-
expressed HER2 Ishikawa cells led to the obvious decrease
of PGE2 and P450arom expression (Figure 4; Table 3).
Discussion
An important member of the epidermal growth factor re-
ceptor (EGFR) family, the proto-oncogene HER-2/neu en-
codes a 185-kD transmembrane glycoprotein with tyrosine
kinase activity [5]. HER-2/neu over-expression typically oc-
curs in the placenta, embryonic epithelial tissue, and several
types of tumor cells. In contrast, HER-2/neu is absent or
minimally expressed in normal tissues [6]. The positive ex-
pression rate of the HER-2/neu protein in endometrial car-
cinoma is associated with clinical staging, a lower degree of
tissue differentiation, and lymph node metastasis [7]. We
have applied RT-PCR and ELISA to detect the expression
of HER-2/neu, COX-2, p450arom and PGE2 in normal
endometrium, hyperplasia endometrium and endometrial
carcinoma respectively. The results showed that the expres-
sion of HER-2/neu was significantly correlated with patho-
logic grading, FIGO staging, and lymph node metastasis.
But it has no correlation with menopausal status [8]. There
are some studies also shows that the HER-2/neu gene con-
tributes to the progression of carcinomas and tumor resist-
ance to chemotherapy [9-11]. A better characterization of
this proto-oncogene can lend insight to the pathogenesis
and molecular mechanisms involved in the development of
endometrial carcinoma.
We have preciously made nude mice transplanted with
Ishikawa cells, which were stably transfected with HER2/
neu plasmid and empty plasmid,respectively. The tumor
volume and weight were measured.It showed that the
tumor formation rate and tumor size in HER2/neuplasmid transfection group were significantly higher than
those of the control group, which suggested that HER2
could promoted the growth of Ishikawa cells. In the
present study, we confirmed that HER-2/neu mRNA and
protein levels were significantly elevated in cells stably
transfected with pcDNA3.1-HER2/neu compared with
non-transfected cells or those transfected with empty vec-
tor. Using these cells, we identified the significant in-
creases in the levels of COX-2 and P450arom. In addition,
the E2 concentration was also significantly increased in
cells stably transfected with pcDNA3.1-HER2/neu com-
pared with non-transfected or empty vector-transfected
groups. As an alternative approach, RNA interference
technology was used for the down-regulation of HER2 ex-
pression in Ishikawa cells. The results showed that inhib-
ition of HER2 in Ishikawa cells significantly induced
the decrease of COX-2 and P450arom expression. Mean-
while, celecoxib, a selective COX-2 inhibitor, inhibited
the expression of PGE2 and P450arom in the over-
expressed HER2 Ishikawa cells. These results indicated
that HER-2/neu induced the upregulation of COX-2,
PGE2 and P450arom to promote the autocrine of E2 in
endometrial carcinoma cells.
As a transmembrane glycoprotein, the cell membrane
portion of HER-2/neu is the primary contributor to trans-
duction of cell proliferation signals [12,13]. The tyrosine
kinase activity of HER-2/neu is essential for COX-2 tran-
scriptional activation [14] and regulates the expression of
COX-2 via multiple pathways [15]. Over-expression of
COX-2, which was detected in endometrial carcinoma,
stimulated the proliferation and angiogenesis of cancer cell
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prostaglandin synthesis [13]. The endometrial prostaglan-
din E2 induced the activity of aromatase (P450arom) by
up-regulating intracellular cAMP levels in endometrial
stromal cells. COX-2 indirectly regulated the expression of
P450arom by influencing the synthesis of PGE2 [17].
P450arom is the rate-limiting enzyme catalyzing the final
step in the conversion from androgen to estrogen.
P450arom determined the levels of estrogen in normal
and abnormal tissues directly, which maintained the
estrogen-related physiologic functions and impacted the
pathogenesis and prognosis of estrogen-dependent dis-
eases [18]. High levels of HER-2/neu have been detected
in endometrial carcinoma tissues and were found to cor-
relate with tumor malignancy [19-21]. Our results sug-
gested that HER-2/neu, as a potential upstream regulatory
molecule in the COX-2/PGE2/P450arom signaling path-
way, could play a critical role in estrogen-dependent endo-
metrial carcinoma. These findings provided an improved
understanding of the molecular mechanisms of estrogen-
dependent endometrial carcinoma, and might instruct to
screen the targets for hormone-dependent gynecologic
tumors related to HER-2/neu.
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